Compile Data Set for Download or QSAR
Report error Found 26779 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase JAK2'
TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633261(US20190276450, Example 1)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633263(US20190276450, Example 1.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633266(US20190276450, Example 1b.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633268(US20190276450, Example 1b.4)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633269(US20190276450, Example 1b.5)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633270(US20190276450, Example 1b.6)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633271(US20190276450, Example 2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633273(US20190276450, Example 2.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633280(US20190276450, Example 2.8)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633283(US20190276450, Example 2.11)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633286(US20190276450, Example 2a.3)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633288(US20190276450, Example 3)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633289(US20190276450, Example 3.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633291(US20190276450, Example 4)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633293(US20190276450, Example 4.3)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633298(US20190276450, Example 6)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633301(US20190276450, Example 7)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633303(US20190276450, Example 9)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633304(US20190276450, Example 10)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633305(US20190276450, Example 11)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633308(US20190276450, Example 12)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633310(US20190276450, Example 12.3)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633313(US20190276450, Example 12.6)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633324(US20190276450, Example 14.4)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633325(US20190276450, Example 14.5)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633326(US20190276450, Example 14.6)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633332(US20190276450, Example 17)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633335(US20190276450, Example 17.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633344(US20190276450, Example 21)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633347(US20190276450, Example 22)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633348(US20190276450, Example 22a)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633349(US20190276450, Example 22.2)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633350(US20190276450, Example 22.4 | US20190276450, Examp...)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633350(US20190276450, Example 22.4 | US20190276450, Examp...)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633352(US20190276450, Example 22.5)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633353(US20190276450, Example 22.6)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633355(US20190276450, Example 22.8)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633357(US20190276450, Example 22.10)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633359(US20190276450, Example 24)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633360(US20190276450, Example 25)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633361(US20190276450, Example 26)
Affinity DataEC50: >2.50E+4nMAssay Description:Erythropoietin (EPO) is known to transduce its signal through EPO receptor via Jak2. Activity against Jak2 was therefore measured by determining inhi...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM50355501(RUXOLITINIB PHOSPHATE | INCB-018424 | RUXOLITINIB ...)
Affinity DataEC50:  12nMAssay Description:Inhibition of JAK2 (unknown origin) assessed as inhibition of STAT5 phosphorylation by cell-based assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM6866(1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b ...)
Affinity DataKd:  31nMAssay Description:Binding affinity to N-terminal TEV-cleavable hexa-histidine tagged human JAK2 JH1 domain (840 to 1132 residues) expressed in baculovirus-infected Sf9...More data for this Ligand-Target Pair
In DepthDetails Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM466382((8S)-N-[(1S,2S)-2- (4-fluoro-3- methyl-phenyl)-2- ...)
Affinity DataEC50:  8.30nMAssay Description:Human baculovirus-expressed JAK1, 2, 3 and TYK2 were purchased from Carna Biosciences, Inc. All four purified enzymes contain only the catalytic doma...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM608046(US11691963, Example I-195-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM515659(US11053219, Example 28 | BDBM515661 | US11053219, ...)
Affinity DataKd:  290nMAssay Description:Binding affinity to wild-type partial length human recombinant JAK2 JH2 (unknown origin) (A829 to G1132 residues) expressed in mammalian expression s...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK2 [536-812,W659A,W777A,F794H](Human)
Yale University

US Patent
LigandPNGBDBM6875(4-({5-amino-1-[(2,6-difluorophenyl)methyl]-1H-1,2,...)
Affinity DataKd:  1.67E+4nMAssay Description:In a flat black bottom 96 well plate (Corning), the buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 20% Glycerol, 0.5 mM TCEP, 0.01% Tween 20) is added&#...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM50596971(CHEMBL5207367)
Affinity DataKd:  3.42E+4nMAssay Description:Binding affinity JAK2 JH1 (unknown origin) assessed as dissociation constant by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Abbvie

US Patent
LigandPNGBDBM633324(US20190276450, Example 14.4)
Affinity DataEC50: >2.00E+4nMAssay Description:Inhibition of JAK2 in human UT7 cells assessed as reduction in erythropoietin induced STAT5 phosphorylation preincubated for 30 mins followed by eryt...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM665112(US20240116892, Compound I-71)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 26779 total ) | Next | Last >>
Jump to: